As of the latest Form 4 filed Jul 6, 2026.
What ANI Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 54 most recent filings for ANIP.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-02 | CAREY STEPHEN P. SVP & CFO | SSale | −3.31K | $86.00 | $285K | Yes (planned) | Form 4 ↗ |
| 2026-07-06 | 2026-07-02 | CAREY STEPHEN P., SVP & CFO | MExercise | +3.31K | $49.51 | $164K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | CAREY STEPHEN P. SVP & CFO | SSale | −2.85K | $84.12 | $240K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | SSale | −500.00 | $82.03 | $41.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | HAUGHEY THOMAS Director | SSale | −2.00K | $80.88 | $162K | Yes (planned) | Form 4 ↗ |
| 2026-06-10 | 2026-05-21 | Thoma Jeanne Director | AAward | +4.36K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-05-21 | Leonard Matthew J Director | AAward | +4.36K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-05-21 | Pera Antonio R Director | AAward | +4.36K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-05-21 | TANNENBAUM RENEE P Director | AAward | +4.36K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-05-21 | HAUGHEY THOMAS Director | AAward | +4.36K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | CAREY STEPHEN P. SVP & CFO | SSale | −3.31K | $80.00 | $265K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | CAREY STEPHEN P., SVP & CFO | MExercise | +3.31K | $49.51 | $164K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | SSale | −500.00 | $78.16 | $39.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Walsh Patrick D Director | SSale | −10.0K | $80.63 | $806K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Gutwerg Ori SVP, GENERICS | SSale | −2.77K | $79.50 | $220K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | SSale | −459.00 | $79.21 | $36.4K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Lalwani Nikhil PRESIDENT & CEO | SSale | −55.0K | $77.57 | $4.27M | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Walsh Patrick D Director | SSale | −3.97K | $80.75 | $321K | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | SSale | −500.00 | $77.95 | $39.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | SSale | −500.00 | $72.62 | $36.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-13 | Mutz Christopher HEAD OF RARE DISEASE | SSale | −3.16K | $71.64 | $227K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | SSale | −4.77K | $74.91 | $357K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Davis Krista SVP, CHIEF HR OFFICER | SSale | −5.09K | $74.13 | $377K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Mutz Christopher HEAD OF RARE DISEASE | SSale | −3.60K | $74.18 | $267K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-07 | Mutz Christopher, HEAD OF RARE DISEASE | FTax | −3.31K | $74.04 | $245K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-07 | Gutwerg Ori SVP, GENERICS | FTax | −3.31K | $74.04 | $245K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-07 | Lalwani Nikhil PRESIDENT & CEO | FTax | −17.1K | $74.04 | $1.26M | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-07 | CAREY STEPHEN P. SVP & CFO | FTax | −5.15K | $74.04 | $381K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Davis Krista SVP, CHIEF HR OFFICER | SSale | −1.49K | $75.00 | $111K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Mutz Christopher HEAD OF RARE DISEASE | SSale | −2.12K | $74.22 | $157K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | CAREY STEPHEN P. SVP & CFO | SSale | −4.00K | $75.56 | $302K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | CAREY STEPHEN P., SVP & CFO | SSale | −3.31K | $75.42 | $250K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | CAREY STEPHEN P., SVP & CFO | MExercise | +3.31K | $49.51 | $164K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-03 | Gutwerg Ori SVP, GENERICS | SSale | −2.06K | $76.50 | $158K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Mutz Christopher HEAD OF RARE DISEASE | SSale | −417.00 | $74.00 | $30.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-03 | 2026-03-03 | Walsh Patrick D Director | SSale | −6.00K | $74.23 | $445K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Davis Krista SVP, CHIEF HR OFFICER | FTax | −1.55K | $73.90 | $115K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | FTax | −1.55K | $73.90 | $115K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Gassert Chad SVP - CORP. DEV. & STRATEGY | FTax | −2.22K | $73.90 | $164K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Mutz Christopher HEAD OF RARE DISEASE | FTax | −2.22K | $73.90 | $164K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Gutwerg Ori SVP, GENERICS | FTax | −2.22K | $73.90 | $164K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Lalwani Nikhil PRESIDENT & CEO | FTax | −12.2K | $73.90 | $903K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | CAREY STEPHEN P. SVP & CFO | FTax | −2.77K | $73.90 | $205K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | FTax | −628.00 | $73.90 | $46.4K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Davis Krista SVP, CHIEF HR OFFICER | AAward | +10.8K | $77.15 | $834K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | AAward | +13.9K | $77.15 | $1.07M | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Gassert Chad SVP - CORP. DEV. & STRATEGY | AAward | +11.1K | $77.15 | $858K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | AAward | +11.1K | $77.15 | $858K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Mutz Christopher HEAD OF RARE DISEASE | AAward | +21.3K | $77.15 | $1.64M | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Gutwerg Ori SVP, GENERICS | AAward | +13.0K | $77.15 | $1.00M | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Lalwani Nikhil PRESIDENT & CEO | AAward | +75.6K | $77.15 | $5.83M | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | CAREY STEPHEN P. SVP & CFO | AAward | +22.2K | $77.15 | $1.72M | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | AAward | +6.02K | $77.15 | $465K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | SSale | −20.0K | $66.62 | $1.33M | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ANIP’s full analysis or the market-wide insider trading feed. The tabs above jump to ANIP’s other SEC data.
Source: SEC Form 4 filings for ANIP, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.